Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101127 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
A Phase 2 study of Sarcoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00101127 is a Phase 2 study of Sarcoma that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 10 states.
The verdict
NCT00101127, a Phase 2 study of Sarcoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel and gemcitabine together with G-CSF or pegfilgrastim works in treating patients with advanced, persistent, or recurrent uterine leiomyosarcoma.
Conditions Studied
Interventions
- DRUG docetaxel
- BIOLOGICAL filgrastim
- BIOLOGICAL pegfilgrastim
- DRUG gemcitabine hydrochloride
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Rush University Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
- Hinsdale Hematology Oncology Associates - Hinsdale
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Carle Cancer Center at Carle Foundation Hospital - Urbana
- CCOP - Carle Cancer Center - Urbana
Georgia
- MBCCOP-Medical College of Georgia Cancer Center - Augusta
- Medical Center of Central Georgia - Macon
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
California
- Kaiser Permanente Medical Center - Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Connecticut
- Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
- New Britain General Hospital - New Britain
Delaware
- CCOP - Christiana Care Health Services - Newark
Indiana
- Saint Anthony Memorial Health Centers - Michigan City
Iowa
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
Louisiana
- Woman's Hospital - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101127
The ClinicalTrials.gov registry entry for NCT00101127 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which docetaxel is the first listed.
NCT00101127 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT00101127 about?
NCT00101127 is a clinical study titled "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma". RATIONALE: Drugs used in chemotherapy, such as docetaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may increase the number of immune cells foun...
What is the current status of trial NCT00101127?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-12.
What conditions does trial NCT00101127 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00101127?
The interventions under investigation include: docetaxel (DRUG), filgrastim (BIOLOGICAL), pegfilgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00101127?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101127 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.